• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Promotion of incompatible allograft acceptance in rhesus monkeys given posttransplant antithymocyte globulin and donor bone marrow. I. In vivo parameters and immunohistologic evidence suggesting microchimerism.

作者信息

Thomas J, Carver M, Cunningham P, Park K, Gonder J, Thomas F

出版信息

Transplantation. 1987 Mar;43(3):332-8. doi: 10.1097/00007890-198703000-00002.

DOI:10.1097/00007890-198703000-00002
PMID:3103273
Abstract

This report extends previous studies demonstrating that prolonged acceptance of incompatible kidney allografts in rhesus monkeys can be achieved by a short recipient rabbit antithymocyte globulin (RATG) treatment course followed by donor bone marrow infusion on day 12 without a requirement for chronic immunosuppression. Serial studies of antilymphocyte cyctotoxic antibody in recipients' sera following RATG injections showed pan-lymphocyte-reactive antibody present until day 10 posttransplant. On days 11 and 12, pan-lymphocyte-reactive antibody was no longer detectable, but cytotoxic antibody specific for mature T cells remained in recipients' sera. These findings might explain the critical time relationship between antithymocyte globulin treatment and donor bone marrow infusion, and further suggest that the tolerance-promoting cell in donor bone marrow is not a mature T cell, but rather a pre-T or a non-T cell. Finally, it was found that this treatment protocol resulted in development of lymphoid nodules in the transplanted kidney that express a CD8-positive, FcIgG-receptor-positive phenotype and appear to be of donor origin. The possibility of a veto cell type of mechanism is discussed as an explanation for the promotion of allograft acceptance in this model.

摘要

相似文献

1
Promotion of incompatible allograft acceptance in rhesus monkeys given posttransplant antithymocyte globulin and donor bone marrow. I. In vivo parameters and immunohistologic evidence suggesting microchimerism.
Transplantation. 1987 Mar;43(3):332-8. doi: 10.1097/00007890-198703000-00002.
2
Promotion of incompatible allograft acceptance in rhesus monkeys given posttransplant antithymocyte globulin and donor bone marrow. II. Effects of adjuvant immunosuppressive drugs.
Transplantation. 1989 Feb;47(2):209-15. doi: 10.1097/00007890-198902000-00002.
3
The development of a posttransplant TLI treatment strategy that promotes organ allograft acceptance without chronic immunosuppression.一种促进器官同种异体移植接受且无需长期免疫抑制的移植后TLI治疗策略的开发。
Transplantation. 1992 Feb;53(2):247-58. doi: 10.1097/00007890-199202010-00001.
4
Kidney allograft tolerance in primates without chronic immunosuppression--the role of veto cells.灵长类动物肾移植在无慢性免疫抑制情况下的耐受——否决细胞的作用
Transplantation. 1991 Jan;51(1):198-207. doi: 10.1097/00007890-199101000-00032.
5
Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts.恒河猴同种异体移植耐受的临床前研究:移植时与供体骨髓一起给予的一种新型抗CD3免疫毒素可诱导对肾同种异体移植的操作性耐受。
Transplantation. 1997 Jul 15;64(1):124-35. doi: 10.1097/00007890-199707150-00022.
6
Enhanced allograft survival in rhesus monkeys treated with anti-human thymocyte globulin and donor lymphoid cells.
Surg Forum. 1979;30:282-3.
7
No synergy between ATG induction and costimulation blockade induced kidney allograft survival in rhesus monkeys.在恒河猴中,抗胸腺细胞球蛋白诱导与共刺激阻断之间不存在协同作用以延长肾移植存活时间。
Transplantation. 2006 Nov 15;82(9):1194-201. doi: 10.1097/01.tp.0000235910.47214.67.
8
Long-term incompatible kidney survival in outbred higher primates without chronic immunosuppression.非近亲繁殖的高等灵长类动物在无慢性免疫抑制情况下的长期肾脏存活。
Ann Surg. 1983 Sep;198(3):370-8. doi: 10.1097/00000658-198309000-00013.
9
Renal allograft tolerance induced with ATG and donor bone marrow in outbred rhesus monkeys.在远交恒河猴中用抗胸腺细胞球蛋白和供体骨髓诱导肾移植耐受。
Transplantation. 1983 Jul;36(1):104-6.
10
Induction of tolerance to heart allografts in rats using posttransplant total lymphoid irradiation and anti-T cell antibodies.
Transplantation. 1993 Dec;56(6):1443-7. doi: 10.1097/00007890-199312000-00032.

引用本文的文献

1
Tregs and Mixed Chimerism as Approaches for Tolerance Induction in Islet Transplantation.调节性T细胞与混合嵌合体作为胰岛移植诱导免疫耐受的方法
Front Immunol. 2021 Jan 29;11:612737. doi: 10.3389/fimmu.2020.612737. eCollection 2020.
2
Historical overview of transplantation.移植的历史概述。
Cold Spring Harb Perspect Med. 2013 Apr 1;3(4):a014977. doi: 10.1101/cshperspect.a014977.
3
Bidirectional alloreactivity: A proposed microchimerism-based solution to the NIMA paradox.双向同种异体反应性:一种基于微嵌合体的解决非我(NIMA)悖论的设想方案。
Chimerism. 2012 Apr-Jun;3(2):29-36. doi: 10.4161/chim.21668. Epub 2012 Apr 1.
4
Hematopoietic chimerism and transplantation tolerance: a role for regulatory T cells.造血嵌合体与移植耐受:调节性 T 细胞的作用。
Front Immunol. 2011 Dec 28;2:80. doi: 10.3389/fimmu.2011.00080. eCollection 2011.
5
The basis of allograft acceptance.同种异体移植接受的基础。
Forum (Genova). 1997;7(Suppl 6):7-18.
6
Pulmonary angiography for the diagnosis of thromboembolic events in the non-human primate.用于诊断非人灵长类动物血栓栓塞事件的肺血管造影术。
Transplantation. 2004 Oct 15;78(7):1025-9. doi: 10.1097/01.tp.0000135462.00668.d7.
7
Tolerance induction for solid organ grafts with donor-derived hematopoietic reconstitution.通过供体来源的造血重建实现实体器官移植的免疫耐受诱导。
Immunol Res. 2000;22(2-3):147-64. doi: 10.1385/IR:22:2-3:147.
8
History of clinical transplantation.临床移植史。
World J Surg. 2000 Jul;24(7):759-82. doi: 10.1007/s002680010124.
9
Chimerism and xenotransplantation. New concepts.嵌合体与异种移植。新概念。
Surg Clin North Am. 1999 Feb;79(1):191-205. doi: 10.1016/s0039-6109(05)70014-1.
10
Transplantation tolerance, microchimerism, and the two-way paradigm.移植耐受、微嵌合体与双向模式。
Theor Med Bioeth. 1998 Sep;19(5):441-55. doi: 10.1023/a:1009924907775.